Immunostimulatory properties of a novel adjuvant administered with inactivated influenza virus vaccine

Wellemans, Vincent; Laurent, S; Hélie, Pierre; Elazhary, Youssef

doi:10.1051/vetres:2006040

Cited by 4 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The overuse and oftentimes the misuse of β-lactams antibiotics are the most important factors promoting the selection and emergence of β-lactam-resistant bacteria in both human and veterinary medicine [ 1 ]. The first β-lactamases, TEM-1, TEM-2 and SHV-1 were found in Escherichia coli and Klebsiella pneumoniae strains and described in the early 1960s, about 15 years after the wide use of penicillin.…”

Section: Introductionmentioning

confidence: 99%

Rapid in vitro detection of CTX-M groups 1, 2, 8, 9 resistance genes by LAMP assays

et al. 2018

View full text Add to dashboard Cite

BackgroundThe prevalence of bacteria producing CTX-M Extended-Spectrum β-lactamases (ESBLs) has increased around the world and some of them became a major cause of infections such as bloodstream or urinary tract infections (UTI). We developed a loop-mediated isothermal amplification (LAMP) assay for a simple, rapid and sensitive detection of the four most common CTX-M groups, namely CTX-M groups 1, 2, 8 and 9.MethodsLAMP primers targeting the four ESBLs CTX-M groups were designed using the Primer Explorer V4 software. The detection limit of the method was tested by serial dilution of reference DNAs. The primer specificity of the LAMP reaction was tested on DNA extracted from six strains producing various group of CTX-M and validated using DNA extracted from CTX-M-resistant clinical isolates (isolated from pus, urine, or blood). Results were compared with those of conventional PCR.ResultsWe were able to detect down to 0.1 pg/ul of DNA using the newly developed LAMP assays whereas the minimal amount detectable for conventional PCR was 50 to 100pg/ul, indicating that the LAMP assay was found to have a detection limit at least 500 to 1000 times lower than the PCR. Additionally, representative genes from the CTX-M groups 1, 2, 8 and 9 were amplified using the designed assay and no cross amplification was observed between the four CTX-M groups, demonstrating the specificity of the LAMP assay. Of the 37 clinical strains tested, the four LAMP assays showed 100% sensitivity and 87%, 97%, 100%, 100% specificity for the CTX-M groups 1, 2, 8 and 9 respectively.ConclusionBeing sensitive, specific, rapid and standard methods, the LAMP assays developed in this study have a potential to be beneficial tools in molecular epidemiology and surveillance studies of the four prevalent EBSLs CTX-M groups even in low cost laboratory.

show abstract

Section: Introductionmentioning

confidence: 99%

Rapid in vitro detection of CTX-M groups 1, 2, 8, 9 resistance genes by LAMP assays

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Failure to anticipate the emergence of an epidemic strain with significant antigenic changes compared to the vaccine strain will greatly reduce vaccine-induced protection. Several studies have suggested that proper adjuvant might improve the immunity of influenza vaccine and reduce the dose of vaccine [5-10]. Aluminum hydroxide (alum) is currently the only human vaccine adjuvant approved for use in the United States, and although it is effective at boosting antibody responses, these responses require repeated administration and tend to generate antiparasitic T helper 2 (T H 2), rather than antiviral and antibacterial T H 1, T cell immunity [11].…”

Section: Introductionmentioning

confidence: 99%

Characterization of cross protection of Swine-Origin Influenza Virus (S-OIV) H1N1 and reassortant H5N1 influenza vaccine in BALB/c mice given a single-dose vaccination

Lin

Chuang

et al. 2013

J Biomed Sci

View full text Add to dashboard Cite

BackgroundInfluenza virus has antigen drift and antigen shift effect, vaccination with some influenza vaccine might not induce sufficient immunity for host to the threat of other influenza virus strains. S-OIV H1N1 and H5N1 influenza vaccines in single-dose immunization were evaluated in mice for cross protection to the challenge of A/California/7/2009 H1N1 or NIBRG-14 H5N1 virus.ResultsBoth H1N1 and H5N1 induced significant homologous IgG, HAI, and microneutralization antibody responses in the mice, while only vaccines plus adjuvant produced significant heterogeneous IgG and HAI antibody responses. Both alum and MPLA adjuvants significantly reduced the S-OIV H1N1 vaccine dose required to elicit protective HAI antibody titers from 0.05 μg to 0.001 μg. Vaccines alone did not protect mice from challenge with heterogeneous influenza virus, while H5N1 vaccine plus alum and MPLA adjuvants did. Mouse body weight loss was also less significant in the presence of adjuvant than in the vaccine without adjuvant. Furthermore, both H1N1 and H5N1 lung viral titers of immunized mice were significantly reduced post challenge with homologous viruses.ConclusionOnly in the presence of MPLA adjuvant could the H5N1 vaccine significantly reduce mouse lung viral titers post H1N1 virus challenge, and not vice versa. MPLA adjuvant induced cross protection with a single dose vaccination to the challenge of heterogeneous influenza virus in mice. Lung viral titer seemed to be a better indicator compared to IgG, neutralization antibody, and HAI titer to predict survival of mice infected with influenza virus.

show abstract

“…Por exemplo, as vitaminas A, D e E, possuem propriedades imunomoduladoras, atuando em vários mecanismos de ativação da resposta imune (CHUA e HANSEN, 2012;LIU at al., 2006;MORA et al, 2008;VERMA et al, 2014;WELLEMANS et al, 2007  Avaliar a existência, ou não, de toxicidade induzida pelas formulações vacinais estudadas;…”

Section: Introductionunclassified

Avaliação de adjuvantes como estratégia para aumentar a produção da vacina influenza no Instituto Butantan

Freitas¹

View full text Add to dashboard Cite

Ao meu Orientador e amigo, Prof. Dr. Wagner Quintilio, por sua paciência, seus ensinamentos, sua dedicação, sua amizade e principalmente por ter lutado ao meu lado para que esse sonho se tornasse realidade. Sem sua perseverança essa conquista não teria sido possível. À Dra. Hisako Gondo Higashi, por todos os ensinamentos transmitidos, pelos exemplos de vida e pelo exemplo de dedicação à produção e desenvolvimento dos imunobiológicos produzidos pelo Instituto Butantan com o único objetivo de contribuir com a saúde pública nacional e internacional. Devo a ela muito de meu conhecimento. Ao Prof. Dr. Isaías Raw, por todos os ensinamentos transmitidos, pelos exemplos de vida, pelo exemplo de pesquisador dedicado e comprometido com a saúde pública de nosso país e do mundo. Devo a ele muito de meu conhecimento. Às pesquisadoras Dra. Josefina Farina Moraes e Dra. Regina Maria Mourão-Fuches, pela ajuda, companhia, apoio e pelos momentos de descontração acompanhados de um bom café. À Profa. Dra. Hiro Goto e ao Prof. Dr. José Ângelo Lauleta Lindoso, por terem me acolhido no Instituto de Medicina Tropical em minha Iniciação Científica e pelo incentivo em seguir a carreira de pesquisa. À Profa. Dra. Enny Fernandes Silva, por ter me incentivado desde a graduação a trilhar os caminhos da pesquisa e desenvolvimento.

show abstract

Immunostimulatory properties of a novel adjuvant administered with inactivated influenza virus vaccine

Cited by 4 publications

References 28 publications

Rapid in vitro detection of CTX-M groups 1, 2, 8, 9 resistance genes by LAMP assays

Rapid in vitro detection of CTX-M groups 1, 2, 8, 9 resistance genes by LAMP assays

Characterization of cross protection of Swine-Origin Influenza Virus (S-OIV) H1N1 and reassortant H5N1 influenza vaccine in BALB/c mice given a single-dose vaccination

Avaliação de adjuvantes como estratégia para aumentar a produção da vacina influenza no Instituto Butantan

Contact Info

Product

Resources

About